HR-Positive and Triple-Negative Metastatic Breast Cancer | Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics:

• Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00)
• Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42)
• Other Targets for ADC Therapy in mBC — Prof Schmid (44:59)

CME information and select publications